Introduction
Herpes simplex virus (HSV) is the prototypic human herpesvirus. The study of viral genetics has resulted in a considerable body of information on the biology and molecular biology of HSV. Generation of HSV mutants has often relied upon drug selection or cotransfection of cells with intact viral and plasmid DNA, usually modified by insertion of a marker gene. Viral mutants containing either point mutations, insertions or deletions are identified by selecting for resistance to drug selection, screening for expression of the plasmid marker, screening for viability in complementing cell lines, or by direct structural characterization. [1] [2] [3] [4] Another way of generating HSV mutants is to use cosmids comprising the HSV genome. Cosmid sets that contain the genomes of the human herpesviruses, VZV, HSV, CMV and EBV have been constructed. [5] [6] [7] [8] Viral plaques are produced by transfecting the cosmid sets into mammalian cells, which results in recombination between the overlapping fragments thereby reconstituting the viral genome.
Specific mutations can be readily introduced into the genome by manipulating cosmid DNA. [5] [6] [7] [8] For example, Cunningham and Davison 6 constructed mutant viruses that were deficient in U L 2 or U L 44 by manipulating an HSV cosmid set. Fraefel et al 9 inactivated the cleavage/packaging function by deleting the 'a' (pac) sequences from the same HSV cosmid set. Transfection of this reagent and an amplicon plasmid, containing HSV ori S and a pac site, into mammalian cells resulted in packaging of only amplicon plasmid DNA into viral particles.
These helper-free amplicons have great utility in gene therapy. [9] [10] [11] However, maintenance of HSV cosmid sequences in E. coli can be problematic due to lack of genetic stability (Refs 6, 12; this report).
To overcome these problems, Messerle et al 13 cloned MCMV as a BAC and Stavropoulos and Strathdee 12 cloned an HSV strain 17 BAC that was reverse engineered from pac-deleted cosmids. However, HSV-BAC generated in this way does not replicate. To create a replication-competent HSV-BAC, we cloned the human herpesvirus HSV-1 strain F genome into a single bacterial artificial chromosome, and tested a method that permits rapid generation of viral mutants using bacterial genetics. We describe the construction of a pac-deficient HSV mutant and demonstrate the ability to generate amplicons. This technology will greatly facilitate manipulation of HSV and potentially other herpesviruses for their use as research tools and as vectors in gene therapy.
Results

Generation of recombinant viruses and BAC plasmids
We used bacterial artificial chromosome (BAC) technology to clone the HSV genome as a single molecule. As a first step, we created an HSV recombinant that contained BAC and marker sequences. We decided to introduce the BAC sequences into the tk locus. pBAC-TK, was constructed with viral tk sequences flanking the signals necessary for chromosomal maintenance in bacteria 14 and the chloramphenicol (cm) resistance gene. This plasmid was cotransfected with infectious HSV-1 DNA into Vero cells and the resultant virus stocks screened with 100 m ACV to isolate drug-resistant viruses. A recombinant virus containing BAC and cm sequences within the tk locus, HSV-BAC, was isolated and plaque purified.
To isolate circular DNA for subsequent transformation into E. coli, Vero cells were infected with HSV-BAC for 2 h and harvested. Isolated circular DNA was electroporated into E. coli and recombinant colonies resistant to cm were subjected to further analysis. Bacterial colonies were subjected to PCR analysis using primer sets specific for HSV genes US6, UL10, UL30 and UL40. Eleven of 11 clones tested were positive for all four primer sets. These results suggested that the genome of HSV had been cloned successfully.
Rescue of infectious virus progeny from HSV-BAC clones One clone, p25, was selected for further analysis. Transfection of p25 into Vero cells resulted in plaque formation after 36 h and complete destruction of the monolayer by 3 days. This virus, r25, was amplified and subjected to further analysis.
To test whether passage of HSV sequences through bacteria was detrimental, the growth rates of the parental input virus and r25 were compared. One-step growth curve experiments revealed that there were no significant differences in the growth rates of these viruses over time in Vero cells ( Figure 1a) . Furthermore, the banding patterns of EcoRV-digested DNA isolated from HSV-BAC, r25 and p25 were identical ( Figure 1b and data not shown). Thus, it appeared that the HSV genome contained within the BAC was stable when passaged in bacteria.
BAC plasmids are stable in bacteria Maintenance of HSV sequences in E. coli can be problematic; the genome contains palindromic sequences that are often unstable in bacteria, eg Ori L . [15] [16] [17] To assess stability of HSV-BAC clone p25, we isolated p25 DNA from bacterial cultures serially passaged every 24 h for 7 days ( Figure 2a) . The restriction pattern of p25 remained unchanged throughout this period. By contrast, the restriction patterns of cosmid clones, containing HSV sequences, 6, 14, 28, 58 and 48 6 were altered significantly. A representative sample is shown in Figure 2a . Furthermore, we often detected alterations in DNA profiles after only 12 h of passage (data not shown). However, Cunningham and Davison 6 had shown that heterogeneity existed in cos 28 isolates. This was due to the instability of Ori L sequences. To ascertain whether Ori L sequences were stable in HSV-BAC, we digested clone p25 or cos 28 with KpnI (Figure 2b ). We could not detect any heterogeneity in the HSV-BAC fragment containing Ori L (Kpn ), indicating that this sequence was stable. Heterogeneity in the bacterial population was assessed by characterizing DNA from five p25 clones and six cosmid 56 clones (Figure 2c ) 6 by digestion with restriction enzymes. Results demonstrated that BAC clones in E. coli were homogeneous whereas cosmid clones were heterogeneous. However, we could not exclude the possibility that HSV-BAC plasmids contain undetected mutations that may be transferred to viral progeny. Nevertheless, it is likely that maintenance of HSV sequences in BACs will be preferable over cosmids for production of reproducible infectious viral DNA for therapeutic or experimental purposes.
Manipulation of BACs containing HSV sequences
We adapted technology developed for chromosomal gene replacement in bacteria; 18 to permit rapid manipulation of BAC sequences. A vector was constructed, pKO5 (Materials and methods), that contains a replacement allele, a temperature-sensitive origin of DNA replication, a marker for positive selection in bacteria, zeocin, and a marker for negative selection, SacB (SacB encodes levansucrase, which is lethal when expressed in E. coli growing on media supplemented with 5% sucrose). Figure 3 illustrates and describes the mutagenesis procedure. Briefly, the in vitro altered sequences are transformed into E. coli and co-integrates (that arise as a result of homologous recombination), are selected by plating cells on cm/zeocin plates at the nonpermissive temperature (43°C). Although the plasmid can integrate into either the BAC or the E. coli chromosome, it is expected that HSV sequences used to target the plasmid will favor HSV-BAC integration. To select for excision and loss of the plasmid, co-integrate colonies are diluted and plated on LB plates containing 5% sucrose at the permissive temperature (Figure 3 ). At the permissive temperature, the plasmid origin is unstable in the BAC, and the plasmid is excised by homologous recombination at either crossover point 1 or 2 ( Figure 3 ). This can result in exchange of the target allele with the mutant allele. Cells that lose the plasmid containing SacB sequences are able to grow under these conditions. Sucrose and cm-resistant colonies are screened for the desired gene replacement event by PCR.
To ascertain whether HSV-BAC sequences were altered by the heatshock procedure, E. coli harboring HSV-BAC were subjected to growth at the nonpermissive temperature and/or sucrose selection and DNA isolated. Extensive restriction enzyme digestions revealed a small deletion in DNA that had undergone heatshock (data not shown). To characterize the deletion, we subcloned and sequenced the appropriate DNA fragments isolated from bacteria that had been incubated at either the permissive or nonpermissive temperature. The deletion extended for 500 bp 5′ of nucleotide 118 565 relative to the strain 17 sequence. 19 However, the deletion did not result in loss of any known regulatory elements and further, rescued virus grew as well as wild-type virus (Figure 4 ). Repetition of the process did not result in any further DNA changes. It is likely that this HSV strain F sequence was toxic to E. coli under heatshock conditions.
Deletion of the pac sites from HSV-BAC clone, p25
To illustrate the power of bacterial genetics in manipulation of HSV genomic sequences, we chose to generate HSV-BAC constructs suitable for amplicon vector production by deleting both cis HSV pac sites from p25. HSV sequences 120 902-125 769 and 126 774-131 249 were cloned into the unique SalI site of pKO5, creating pKO5-LARA (Materials and methods; Figure 5a ). This construct lacks HSV sequences, 125 770-126 773, that contain the pac site. pKO5-LARA was transformed into E. coli containing p25 and plated on LB plates containing cm and zeocin at the nonpermissive temperature. To select for excision and loss of plasmid, six co-integrate colonies were diluted and plated on LB plates containing 5% sucrose at the permissive temperature then replica plated on to either cm or zeocin plates to confirm the presence of BAC and loss of plasmid sequences (Figure 5b) . PCR, using primers that flank the putative deletion demonstrated that pac sequence deletions were present in approximately 30% of the BAC clones (Figure 5c and data not shown). The deletions were confirmed by Southern blotting (data not shown). One clone, p45, was picked for further analysis. Restriction enzyme digests indicated that: (1) the internal pac sequence was absent from clone p45; and (2) the alteration in the DraI banding profile of p45 was exactly as predicted from sequence information (Figure 5d ). The procedure was repeated to delete the remaining pac sequence from p45. Several clones, p45-12, p45-14, and p45-25, were identified and subjected to Southern blotting analysis. Results indicated that the mutant allele carried on the plasmid had replaced both BAC pac sequences (Figure 5e and data not shown). Furthermore, either EcoRV (Figure 5f ), EcoRI, SalI, SacI, or DraI (not shown) restriction patterns of DNA extracted from p45, p45-12, p45-14 and p45-25, confirmed that BAC plasmids remained stable during the mutagenesis procedure.
HSV-BAC DNA can package amplicons
To test infectivity and plaque formation, we transfected either p25 or p45-25 into Vero cells. Wild-type HSV-BAC, p25, generated plaques 36-48 h after transfection whereas we could not detect plaques in p45-25-transfected cells despite passaging them for 28 days. Trans functions were tested by determining the ability of p45-25 (HSVBAC⌬a 2 ) DNA to package amplicon plasmid DNA. Amplicon plasmids containing lacZ under the HSV IE4/5 promoter were cotransfected with pac-deleted HSV sequences of either p45-25, or cosmid DNA. 6, 9 Cells were harvested after 4 days and infectious amplicon particles quantified by infecting fresh monolayers and counting blue cells or viral plaques (Table 1 ). The result of this experiment indicated that both HSV-BAC DNA and cosmid DNA packaged amplicons. However, we could not accurately quantify the p45-25 packaging efficiency, as in some instances we could detect helper virus that had arisen via recombination between the homologous sequences present in both p45-25 and the amplicon plasmid, that is, Ori S . These data suggest that despite the advantage of DNA stability, HSV-BAC will need to be further modified before it becomes a useful vector for production of helper-free amplicons for gene therapy.
Discussion
Construction of viral herpesvirus mutants by conventional means can often be a lengthy process. Usually, the mutant allele is cotransfected into mammalian cells with infectious viral DNA, and recombinant viruses screened for by standard molecular techniques. Once identified, the recombinant virus needs to plaque purified to remove contaminating nonrecombinant virus.
To facilitate the process of human herpesvirus genome manipulation, the genomes of VZV, HSV, CMV and EBV were cloned as cosmids. [5] [6] [7] [8] Several mutant viruses have been rapidly constructed by manipulating these cosmids.
5-8 However, we and others have found that maintenance of HSV sequences in cosmids is not stable (Refs 6, 12; Figure 2a) . Furthermore, as the starting material is heterogeneous (Figure 2c) , the generated mutant viruses may contain unknown mutations at other sites. Thus, the properties of HSV preparations that are produced from cosmid DNA may vary from batch to batch. Obviously, this has important ramifications if HSV cosmid sets are used to generate helper-free amplicons for use in gene therapy. [9] [10] [11] To overcome the deficits of cosmid mutagenesis and to expedite and simplify the procedure of mutant virus construction, we adapted technology that was developed for gene replacement in E. coli. 18 The procedure requires two reagents, an HSV-BAC and a gene replacement vector. The construction of the first reagent follows standard virological techniques and exploits the fact that the HSV genome circularizes in the nucleus of infected cells. 20, 21 Other herpesvirus BACs have been constructed. Messerle et al 13 and Stavropoulos and Strathdee 12 have respectively cloned a murine cytomegalovirus genome as a BAC from infectious virus and an HSV strain 17 BAC that was reverse engineered from cosmids. The second reagent, the gene replacement vector, contains a mutant allele, either an insertion, deletion or point mutation. The vector is transformed into HSV-BAC containing bacteria and subjected to selection as outlined (Figure 3) . Depending upon the length of the flanking sequence that is used for homologous recombination, these frequencies can occur approximately 50% of the time. Thus, as many as half of the sucrose-resistant colonies may contain mutant BAC sequences. PCR can be used to screen for the desired mutation at this stage as there are no plasmid sequences present in bacteria that could give a false PCR result (see Figure 5b ). Once detected, BAC DNA can be harvested from bacteria and transfected into mammalian cells and virus recovered 2 days later. Taken together, this procedure allows generation and isolation of mutant viruses within 7 days. Moreover, all mutant vectors are clonally derived and isolated in the absence of wild-type virus; thus, there is no need to plaque purify recombinant viruses. However, we did observe that some HSV strain F sequences are toxic to E. coli at 43°C. These sequences, reiterated repeats upstream of the lat promoter, were deleted in bacteria. The number and nature of these repeats vary between and within HSV strains. 22, 23 However, analysis of the rescued virus indicated that there were no growth defects ( Figure 4 ) and experiments are underway to address the behavior of the mutant virus in vivo. Nevertheless, once deleted, the HSV-BAC is stable and mutagenesis could be repeated without any other detectable changes. It is likely that use of this procedure in other bacterial strains could prevent this deletion from occurring, and this remains to be investigated.
To illustrate the ease with which we could manipulate the HSV genome, we deleted the pac sites of HSV-BAC. This reagent, p45-25, was able to package amplicon plasmid (Table 1) . However, in several transfections, we could detect the presence of helper-virus. It is likely that the helper-virus arose as a result of recombination between the Ori S sequences that are present in both the amplicon and HSV-BAC plasmids. However, the amounts of contaminating virus were low, ranging from undetectable to a ratio of 1 helper-virus: 1 amplicon. Generation of HSV-BAC-derived helper-free amplicons will require that there are no homologous sequences between amplicon and HSV-BAC plasmids. This could be accomplished by deleting the Ori S sequences from p45-25; Igarashi and colleagues 24 determined that an Ori Sdeleted HSV-1 could replicate nearly as well as wildtype virus.
We chose to insert the BAC sequences into the tk locus, because we can readily select for insertion or deletion of BAC sequences. This strategy is useful as BAC sequences may be problematic if the mutated virus is to be used in a clinical setting. However, any viruses that are produced from our reagent will be TK negative and thus deficient for most animal studies. Nevertheless, it is relatively straightforward to introduce the BAC sequence to other loci in the HSV genome.
In conclusion, we have developed a new methodology that overcomes the deficits of cosmid technology. The BAC/KO5 system will greatly facilitate manipulation of HSV and other herpesviruses for investigating basic biological questions and for their use as vectors.
Materials and methods
Viruses and cells
Vero and Vero 2-2 cells 25 were propagated and virus assayed for acyclovir susceptibility as described by Horsburgh et al. 26 Virus titers were determined in triplicate on Vero cells. Recombinant viruses were plaque purified two times and the mutation(s) confirmed by Southern blot hybridization and PCR analysis.
Plasmids
Plasmid pTK-AB was created by subcloning the BglII/EcoRI fragment from pXhoIf, strain 17, (Chris Preston, University of Glasgow) into the BamHI/EcoRI sites of pHSVlac. 27 The tk containing plasmid, BH13, strain 615.9, 28 was digested with PstI and XhoI, to release the 3′ end of the tk gene, and the fragment subcloned into the PstI/XhoI site of pSC1180, creating plasmid TK-CD. Plasmids TK-AB and TK-CD were digested with HindIII/MscI and HindIII/SalI respectively and the fragments subcloned into the HpaI/SalI sites of pBelobac 29 to create plasmid pBAC-TK. pKO5 was generated by cloning the zeocin gene as a blunt-ended SspI-StyI fragment into the NaeI site of pKO3 18 and deleting the chloramphenicol (cm) gene by digesting with BstBI and religating. Construction of pKO5-LARA was as follows. The BstEII fragment containing HSV sequences 120 902-125 769 was blunt-ended and cloned into the EcoRV site of pBluescript (Stratagene, La Jolla, CA, USA) creating pLA. pK1-2 30 was digested with EcoRI and HSV sequences 126 774-131 249 were cloned into the EcoRI site of pLA creating pLARA. pLARA was digested with SalI and the HSV containing sequences purified and cloned into SalI digested pKO5.
PCR PCR-amplified fragments were obtained using viral genomic DNA or plasmid DNA as template and the oligonucleotide primers listed below. Taq DNA polymerase (Promega, Madison, WI, USA) was used to amplify the region of interest with 30 cycles (95°C, 1 min, 55°C, 1 min, 72°C, 1 min) being performed in a Perkin Elmer Geneamp 2400 (Norwalk, CT, USA). The primers that were used in this work are as follows.
Chloramphenicol 5′AGGCCGGATAGCTTGTGC and 5′CGGAACAGAGAGCGTCACA U S 6 5′CCGAATGCTCCTACAACAAG and 5′GTCTTCC GGGGCGAGTTCTG U L 10 5′GGTGTAGCCGTGCCCCTCAG and 5′GCAGAT-ACGTCCCGCTCAGG U L 30 5′ATCAACTTCGACTGGCCCTTC and 5′CCGTA-CATGTCGATGTTCACC U L 40 5′ACCGCTTCCTCTTCGCTTTC and 5′CCCGCA-GAAGGTTGTTGGTG Virus construction pBAC-TK was digested with HindIII and cotransfected into Vero cells with infectious HSV-1 strain F DNA as described by Chiou et al. 31 DNA from plaques that were resistant to 100 m ACV was screened by PCR using primers that correspond to chloramphenicol sequences (see above). From each of two independent transfections, two recombinant viruses were plaque purified two times and the mutation confirmed by Southern blot hybridization. One virus, HSV-BAC, was subjected to further analysis.
Isolation of HSV-BAC DNA and BAC plasmids
At a multiplicity of infection (MOI) of 3, 100 mm dishes of confluent Vero cells were infected with HSV-BAC.
Infections were allowed to proceed for 2 h, the supernatants removed and 1 ml of DNAzole (Gibco, BRL, Burlington, ON, Canada) added. DNA, obtained from the cell lysate by following the manufacturer's protocol, was resuspended in 100 l of TE. One microliter of DNA was added to an equal volume of water and electroporated into 25 l of electro-competent E. coli, strain DH10B, using a cell-porator (Gibco) and conditions recommended by the manufacturer. The bacteria were allowed to recover by incubating at 37°C in LB broth, plated out on to LB agar plates containing chloramphenicol (12.5 g/ml) and incubated at 37°C overnight. BAC plasmids were isolated from E. coli using an alkaline-lysis procedure and screened by PCR. Four sets of primers were used to amplify sequences in U S 6, U L 10, U L 30 and U L 40. Two micrograms of DNA from clones that were positive for all primer sets were transfected into a 100 mm dish of Vero cells using 18 l of lipofectamine and incubated at 34°C. Viral plaques were observed 2 days after transfection.
BAC mutagenesis
Bacteria (strain RR1) containing p25 (see text) were made electrocompetent using standard procedures. 32 Forty microliters of electrocompetent cells were mixed with 2 l of pKO5-LARA in an ice-cold microfuge tube and transferred to a 0.1 cm electroporation cuvette (BioRad, Mississauga, ON, Canada) and electroporated at 1.8 kV with 25 farad and 200 ohm resistance. The bacteria were allowed to recover for 1 h at 30°C in 1 ml of LB, plated on zeocin/chloramphenicol LB agar plates and incubated overnight at 43°C. The following day, six colonies were picked and serially diluted into LB, plated on chloramphenicol/5% sucrose LB plates and incubated overnight at 30°C. To confirm loss of replacement vector, sucrose-resistant colonies were replica plated on to zeocin LB plates and incubated at 30°C. Potential positive colonies (sucrose/chloramphenicol resistant, zeocin sensitive) were picked directly into PCR buffer. Mutations were confirmed by PCR and Southern hybridization. Mutant vectors were tested for growth on 2-2 and Vero cells.
Amplicon production 2-2 Cells were cotransfected with 1, 2, or 4 g of either p45-25 (HSV-BAC⌬a 2 ) and pHSVlac 11 or with a pacdeleted HSV cosmid set and pHSVlac exactly as described by Fraefel et al. 9 Cells were harvested after 4 days, frozen and thawed three times, the cellular debris removed by centrifugation and the supernatant used to infect fresh monolayers. Titers were calculated by serially diluting lysates and counting either plaques or transduced blue cells after staining with X-Gal as described by Fraefel et al. 9 Transfections were repeated six times using the optimally determined DNA concentration to determine titer.
